Abbott Laboratories Stock Drops 1.84% in Two Days, Trading Volume Ranks 84th

Abbott Laboratories, Inc. (ABT) experienced a decline of 1.59% on May 21, 2025, marking its second consecutive day of losses, with a total decrease of 1.84% over the past two days. The company's trading volume reached 9.64 billion, ranking 84th in the day's market activity.

Abbott Laboratories has announced that it will be hosting its annual meeting of shareholders on June 12, 2025. The meeting will be held virtually, allowing shareholders to participate remotely. The company has also released its proxy statement, which includes important information about the meeting and the proposals that will be voted on.

Abbott Laboratories has received approval from the U.S. Food and Drug Administration (FDA) for its new FreeStyle Libre 3 system. This system is designed to continuously monitor glucose levels in people with diabetes, providing real-time data to help manage the condition more effectively. The approval is a significant milestone for Abbott, as it expands its portfolio of diabetes management solutions.

Abbott Laboratories has reported strong financial results for the first quarter of 2025. The company's revenue increased by 5% year-over-year, driven by robust sales in its diagnostics and nutrition segments. The company's earnings per share also saw a significant increase, reflecting its strong operational performance and cost management efforts.